TB Alternative Assets Ltd. Acquires Shares of 652,373 Moderna, Inc. (NASDAQ:MRNA)

TB Alternative Assets Ltd. acquired a new stake in shares of Moderna, Inc. (NASDAQ:MRNA - Free Report) in the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 652,373 shares of the company's stock, valued at approximately $18,495,000. Moderna accounts for approximately 4.3% of TB Alternative Assets Ltd.'s investment portfolio, making the stock its 10th largest holding. TB Alternative Assets Ltd. owned 0.17% of Moderna as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors and hedge funds have also bought and sold shares of MRNA. Blue Trust Inc. grew its holdings in Moderna by 53.1% during the fourth quarter. Blue Trust Inc. now owns 1,119 shares of the company's stock valued at $47,000 after purchasing an additional 388 shares during the period. Caprock Group LLC bought a new position in Moderna during the fourth quarter valued at $203,000. abrdn plc grew its holdings in Moderna by 28.1% during the fourth quarter. abrdn plc now owns 315,912 shares of the company's stock valued at $12,842,000 after purchasing an additional 69,360 shares during the period. Yousif Capital Management LLC grew its holdings in Moderna by 3.9% during the fourth quarter. Yousif Capital Management LLC now owns 42,171 shares of the company's stock valued at $1,753,000 after purchasing an additional 1,568 shares during the period. Finally, Sumitomo Mitsui DS Asset Management Company Ltd grew its holdings in Moderna by 1.9% during the fourth quarter. Sumitomo Mitsui DS Asset Management Company Ltd now owns 34,863 shares of the company's stock valued at $1,450,000 after purchasing an additional 657 shares during the period. 75.33% of the stock is owned by institutional investors.

Moderna Stock Up 5.1%

NASDAQ MRNA opened at $27.46 on Friday. The stock's 50-day simple moving average is $26.11 and its two-hundred day simple moving average is $33.50. Moderna, Inc. has a twelve month low of $23.15 and a twelve month high of $152.28. The company has a market capitalization of $10.62 billion, a price-to-earnings ratio of -2.96 and a beta of 1.86.

Moderna (NASDAQ:MRNA - Get Free Report) last released its quarterly earnings results on Thursday, May 1st. The company reported ($2.52) earnings per share for the quarter, beating analysts' consensus estimates of ($2.92) by $0.40. Moderna had a negative return on equity of 28.74% and a negative net margin of 110.04%. The business had revenue of $108.00 million for the quarter, compared to the consensus estimate of $130.35 million. During the same quarter last year, the business posted ($3.07) earnings per share. The company's revenue for the quarter was down 35.3% on a year-over-year basis. On average, equities analysts expect that Moderna, Inc. will post -9.61 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of equities analysts have recently commented on the company. JPMorgan Chase & Co. cut their price target on Moderna from $33.00 to $26.00 and set an "underweight" rating for the company in a report on Thursday, May 22nd. UBS Group cut their price target on Moderna from $78.00 to $70.00 and set a "buy" rating for the company in a report on Friday, May 2nd. William Blair reaffirmed a "market perform" rating on shares of Moderna in a report on Monday, June 2nd. Citigroup assumed coverage on Moderna in a report on Thursday, March 13th. They issued a "neutral" rating and a $40.00 price target for the company. Finally, Royal Bank of Canada cut their price target on Moderna from $32.00 to $28.00 and set a "sector perform" rating for the company in a report on Friday, May 2nd. Four analysts have rated the stock with a sell rating, fifteen have issued a hold rating, three have given a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat, Moderna currently has an average rating of "Hold" and a consensus target price of $53.58.

About Moderna

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.

Want to see what other hedge funds are holding MRNA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Moderna, Inc. (NASDAQ:MRNA - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.